Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 1/2

Tests multi-CAR-T cell therapy in hard-to-treat B cell lymphomas

Tests modified T cells against B cell lymphoma that resisted other treatments.

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
Shenzhen, ChinaSee the site
Trial code
Registry title
Multi-CAR-T Cells Targeting B Cell Lymphomas
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
11 people, planned
Starts
1 Jun 2027
Expected to end
31 Dec 2030
Type of study
Interventional
Treatments tested
  • 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with hard-to-treat B cell lymphoma, including lymphoma in the brain and spinal cord area, to test CAR-T cell treatment.

Age
From 6 months to 75 years
Sex
Men and women
Disease stage
B cell lymphoma that has resisted treatment, including primary mediastinal B cell lymphoma and lymphoma involving the central nervous system. The lymphoma cells must show CD19 and/or CD22, CD70, PSMA, CD13, CD79b or GD2 on their surface.
Earlier treatment
A previous failed CAR-T treatment means a person cannot join. No systemic steroid treatment within a week before the treatment.
Biomarker or test result
CD19 and/or CD22, CD70, PSMA, CD13, CD79b or GD2 on the surface of the lymphoma cells.

Main reasons for not taking part

  • Another active disease that makes it hard to judge the response to treatment
  • An infection that cannot be controlled (bacterial, fungal or viral)
  • Living with HIV
  • Active HBV or HCV infection
  • Pregnant or nursing mothers

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age older than 6 months
  • Primary B cell lymphoma surface expression of CD19 and/or CD22/CD70/PSMA/ CD13/CD79b/GD2 molecules
  • The KPS score over 80 points, and survival time is more than 1 month
  • Greater than Hgb 80 g/L
  • No contraindications to blood cell collection

Who cannot take part

  • Pregnant and nursing mothers.6. under systemic steroid treatment within a week of the treatment
  • Prior failed CAR-T treatment
  • Accompanied with other active diseases, and difficult to assess response after treatment
  • Bacterial, fungal, or viral infection, unable to control
  • Living with HIV
  • Active HBV and HCV infection

Where in China

  • Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, Ph.DNo longer taking part

About the trial

What the trial wants to find out

This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

The group in the trial

  • 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2Treatment being tested

    Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas
Plain-language title
Tests multi-CAR-T cell therapy in hard-to-treat B cell lymphomasGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 November 2026